ClinicalTrials.gg
RecruitingNCT07832695Updated Sep 22, 2026

Effects of Repetitive Transcranial Magnetic Stimulation (rTMS)-Primed Self-controlled Practice in People With Parkinson's Disease

An interventional study of Repetitive Transcranial Magnetic Stimulation (rTMS) and Physical therapy in Parkinson Disease (PD), sponsored by National Taiwan University Hospital. Recruiting at 1 site in Taiwan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-22.

Sponsored by National Taiwan University Hospital · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 27 studies in Parkinson Disease by National Taiwan University Hospital — 9 open to participants now, 10 under way, none of them phase 3. Parkinson Disease · National Taiwan University Hospital.

Planned enrollment
4th of 24
90 · median 50
Started
2026
the only one that year
No phase
22 of 27
8 open now
Registered
27th of 27
by date

Among the 27 studies in Parkinson Disease by National Taiwan University Hospital, this one is the 4th largest by planned enrollment of the 24 interventional ones that give a count, is the only one that started in 2026, is one of 22 with no phase, and was the 27th registered.

Parkinson Disease

4,581 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

9 of the 27 studies in Parkinson Disease by National Taiwan University Hospital are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 313 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Parkinson Disease by National Taiwan University Hospital, or all of them as a file.
02

Study summary

Parkinson's disease (PD) is commonly associated with impaired motor learning and reduced motivation, both of which can negatively influence rehabilitation outcomes. Prior cross-sectional evidence suggests that providing individuals with PD self-controlled access to training parameters enhances motor learning, increases motivation, and facilitates cognitive processing. However, the effects of self-controlled practice implemented across repeated training sessions remain underexplored. Moreover, given that dysfunction of fronto-striatal circuits in PD may limit the neuroplastic response to motor training alone, adjunctive neuromodulatory priming approaches such as repetitive transcranial magnetic stimulation (rTMS) may be required to optimize therapeutic efficacy. To date, it remains unclear whether rTMS priming combined with self-controlled motor training yields superior clinical benefits, and whether stimulation of different cortical targets produces differential effects. In particular, the dorsolateral prefrontal cortex (DLPFC), a key region involved in cognitive control and motivation, may offer distinct therapeutic effects compared with stimulation of the primary motor cortex (M1). This study aims to investigate the effects of rTMS priming over the DLPFC or M1, followed by self-controlled motor training, in individuals with PD, and to compare these effects with a sham stimulation condition.

This single-blinded, randomized control trial will recruit 90 individuals with PD, who will be matched into 45 pairs and randomly assigned to one of three stimulation conditions: DLPFC, M1, or sham. Within each pair, one participant will be allocated to a self-controlled practice condition, and the other to a yoked (paired-control) condition that receives identical training content determined by their matched counterpart. Each participant will undergo 12 intervention sessions. In each session, rTMS will be applied first as a priming intervention, followed immediately by 45 minutes of standardized physical therapy-based motor training. For the DLPFC group, stimulation will target the left DLPFC; for the M1 group, stimulation will be applied over the M1 contralateral to the more affected limb; and for the sham condition, the coil will be rotated 90 degrees to mimic stimulation without effective cortical activation. During the training phase, participants in the self-controlled condition will be allowed to select aspects of their practice content, whereas yoked participants will follow the corresponding selections made by their matched partner.

The primary outcome measure is the Unified Parkinson's Disease Rating Scale (UPDRS). Secondary outcomes include assessments of cognitive function, apathy, non-motor symptoms, gait performance, balance, functional mobility, falls efficacy, and quality of life. Neurophysiological outcomes will be assessed using single- and paired-pulse TMS to evaluate corticospinal excitability and cortico-cortical connectivity, particularly between DLPFC and M1 networks. All assessments will be conducted in the medication-on state by blinded evaluators at baseline, immediately post-intervention, and at one-month follow-up. Data will be analyzed using mixed-effects repeated-measures ANOVA to examine group-by-time interactions and intervention effects. This study seeks to determine whether rTMS priming over cognitive-control versus motor networks differentially enhances the efficacy of self-controlled motor training, and whether such combined interventions can induce sustained improvements in motor and non-motor outcomes in PD.

03

Conditions studied

  • Parkinson Disease (PD)

Browse trials for

Keywords

  • Motor learning
  • Repetitive Transcranial Magnetic Stimulation (rTMS)
  • Priming
  • Self-controlled practice
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • diagnosed of PD by neurologists and age above 18 years old
  • able to follow the researcher's instruction (the ≥ 24)
  • able to stand and walk independently for 10 minutes with or without assistive devices

Exclusion criteria

Exclusion Criteria:

  • have neurological disorders other than PD (e.g., Parkinson plus syndrome, cognitive impairment, dementia, stroke)
  • have to receive TMS, such as a pacemaker or deep brain stimulator implanted in the body
  • a self-history of seizure or a family history of epilepsy
  • pregnancy
  • unstable medical conditions that is not under control
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Single (Outcomes assessor)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    DLPFC-self

    Device: Repetitive Transcranial Magnetic Stimulation (rTMS) · Behavioral: Physical therapy

  • Experimental
    DLPFC-yoked

    Device: Repetitive Transcranial Magnetic Stimulation (rTMS) · Behavioral: Physical therapy

  • Experimental
    M1-self

    Device: Repetitive Transcranial Magnetic Stimulation (rTMS) · Behavioral: Physical therapy

  • Experimental
    M1-yoked

    Device: Repetitive Transcranial Magnetic Stimulation (rTMS) · Behavioral: Physical therapy

  • Sham comparator
    Sham-self

    Device: Repetitive Transcranial Magnetic Stimulation (rTMS) · Behavioral: Physical therapy

  • Sham comparator
    Sham-yoked

    Device: Repetitive Transcranial Magnetic Stimulation (rTMS) · Behavioral: Physical therapy

Interventions

  • DeviceRepetitive Transcranial Magnetic Stimulation (rTMS)

    The iTBS paradigm will be used to prime the neuronal excitability of the DLPFC or M1 based on the group allocation. The patterns of iTBS are triplets of stimuli at 50Hz frequency repeated in 5Hz bursts with a 2 second train repeated every 10 seconds for a total of 190 seconds, which will result in 600 stimulation pulses. The intensity will be set at 80%-120% of motor threshold of the tibialis anterior (TA) or first dorsal interosseous (FDI) muscle of the more affected limb. As for the sham rTMS groups, the coil will be placed over the M1 hotspot but turned 90 degrees away so that the surface of the coil will be 90 degrees perpendicular to the scalp.

  • BehavioralPhysical therapy

    After the iTBS priming procedure, the participants will receive 45 minutes of one-on-one physical therapy training targeting whole body and lower extremity function. Each training session will involve flexibility exercise, gait training, balance training, resistance exercise, or cognitive-motor dual task training.

06

What researchers measure

Primary outcomes

  1. Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS)

    The MDS-UPDRS is currently the gold-standard scale used in the clinics as well as research to determine the disease severity of PD. The MDS-UPDRS contains four parts: (1) non-motor aspects of experiences of daily living, (2) motor aspects of experiences of daily living, (3) motor examination, and (4) motor complications. Each item is scored from 0 (no symptom) to 4 (most severe symptom), and the total score range for the MDS-UPDRS is from 0 to 260 with a higher score indicates greater disease severity.

    Time frame: Three time points: pre-test (before intervention, 0 week), post-test (after all intervention sessions, up to 4 weeks), follow-up test (one month after intervention, up to 8 weeks)

Secondary outcomes

  1. Montreal cognitive assessment (MoCA)

    The MoCA will be used to assess general cognitive function of the participants. It examines various cognitive functions, including set-shifting, visuospatial processing, abstract thinking, short-term memory, attention, verbal fluency, calculation, orientation, and digit span abilities. The total score of MoCA is 30 with a higher score suggests better cognitive function, and a score below 26 would suggest an increased risk of cognitive decline.

    Time frame: Three time points: pre-test (before intervention, 0 week), post-test (after all intervention sessions, up to 4 weeks), follow-up test (one month after intervention, up to 8 weeks)

  2. Short-form Lille apathy rating scale (LARS)

    The LARS scale has 12 items categorized into 7 domains: everyday productivity, interests, take the initiative, novelty seeking, motivation-voluntary actions, emotional responses, and social life. Each item is scored on a 5-point Likert scale or a binary yes/no scale. The score ranges from -15 to 15 with a higher score suggests more apathetic symptoms. It has been established that a short-form LARS score ≥ -7 points is the cut-off score for identifying apathy in PD.

    Time frame: Three time points: pre-test (before intervention, 0 week), post-test (after all intervention sessions, up to 4 weeks), follow-up test (one month after intervention, up to 8 weeks)

  3. Non-motor symptoms scale for Parkinson's disease (NMSS)

    The NMSS is a specifically designed 30-item scale to assess various non-motor symptoms of PD. It evaluates severity (score 0-3) and frequency (score 1-4) across nine non-motor domains: cardiovascular including falls, sleep/fatigue, mood /cognition, perceptual problems/hallucinations, attention/ memory, gastrointestinal tract, urinary, sexual function, and miscellaneous.

    Time frame: Three time points: pre-test (before intervention, 0 week), post-test (after all intervention sessions, up to 4 weeks), follow-up test (one month after intervention, up to 8 weeks)

  4. Gait performances

    To measure walking ability, the participants will be asked to walk along a 10-meter hallway with their comfortable walking speed and fastest walking speed in single- and dual-task conditions. The Physilog®5 system (Gait Up, Renens, Switzerland) including two inertial sensors with built-in 3D accelerometers and gyroscopes will be fixated to the shoelaces area of both feet to record the walking data. The data will be sampled at a rate of 128Hz and will then be analysed by the Gait Up© gait analysis package (Gait Up SA, Switzerland). Gait parameters of interest include velocity, step length, cadence, foot-strike angle, and foot clearance.

    Time frame: Three time points: pre-test (before intervention, 0 week), post-test (after all intervention sessions, up to 4 weeks), follow-up test (one month after intervention, up to 8 weeks)

  5. New freezing of gait questionnaire (NFOG-Q)

    The NFOG-Q is a self-reported questionnaire to determine the presence and severity of freezing of gait in people with PD. It contains 9 questions with the first question asking the participants whether they have experienced freezing episodes in the past 1 month. If an individual answers 'no' to this question, he/she will be classified as non-freezer and will not need to answer the following questions. One the other hand, if a person answers 'yes' to the first question, he/she will be asked to further complete the rest of the questions regarding the severity and duration of the freezing episodes.

    Time frame: Three time points: pre-test (before intervention, 0 week), post-test (after all intervention sessions, up to 4 weeks), follow-up test (one month after intervention, up to 8 weeks)

  6. 5-time sit to stand test (5TSTS)

    The 5TSTS will be used to evaluate the lower extremity muscle strength and endurance. Using a standardized chair, the participants will be requested to stand up and then sit down as quickly as possible for 5 times, and the time to complete the test will be recorded.

    Time frame: Three time points: pre-test (before intervention, 0 week), post-test (after all intervention sessions, up to 4 weeks), follow-up test (one month after intervention, up to 8 weeks)

  7. Timed up and go (TUG) test

    The TUG is a gold standard to measure dynamic balance and gait ability. The participant will first sit on a standardized chair with back supported. After a GO signal, he/she will stand up, walk 3 meters, turn 180°, walk back and then sit down. The participants will be instructed to walk with their preferred and fastest walking speeds.

    Time frame: Three time points: pre-test (before intervention, 0 week), post-test (after all intervention sessions, up to 4 weeks), follow-up test (one month after intervention, up to 8 weeks)

  8. Mini balance evaluation systems test (Mini-BESTest)

    The Mini-BESTest assesses 4 aspects of balance ability, including anticipatory postural adjustments, reactive postural control, sensory orientation, and dynamic gait. It contains 14 items, and each item is scored on a 0-2 ordinal scale, with a total score of 28 points. A higher score indicates better balance control.

    Time frame: Three time points: pre-test (before intervention, 0 week), post-test (after all intervention sessions, up to 4 weeks), follow-up test (one month after intervention, up to 8 weeks)

  9. Activities-Specific Balance Confidence (ABC) scale

    The ABC scale will be utilized to assess an individual's confidence level of not falling when performing daily activities at home and in the community. Sixteen indoor and outdoor activities are involved in the scale, and the participants will rate their confidence level of not falling from 0 (no confidence at all) to 100 (very confident) when performing the activities. An average score of these questions will then be calculated with a higher score suggests greater confidence of not falling.

    Time frame: Three time points: pre-test (before intervention, 0 week), post-test (after all intervention sessions, up to 4 weeks), follow-up test (one month after intervention, up to 8 weeks)

  10. Parkinson's Disease Questionnaire-39 (PDQ-39)

    The PDQ-39 is a specifically designed self-report questionnaire to determine quality of life in individuals with PD. The questionnaire contains 39 health-related items, and the participants will answer these questions based on their own experience in the past one month. Each item is score on a 5-point Likert scale with a lower score suggests less difficulty performing the task. As a result, a lower total score will indicate better quality of life.

    Time frame: Three time points: pre-test (before intervention, 0 week), post-test (after all intervention sessions, up to 4 weeks), follow-up test (one month after intervention, up to 8 weeks)

  11. Motivation questionnaire

    The motivational questionnaire will be used to determine their motivation level after each training session. It consists of perceived competence, task interest/enjoyment, and autonomy. The questions for perceived competence and task interest/enjoyment are directly taken from Intrinsic Motivation Inventory (IMI), which originally consists of 22 items with 4 subscales including interest/enjoyment, perceived competence, perceived choice, and pressure/tension (McAuley et al., 1989). As for autonomy, the questions are referenced from the autonomy subscale used in a study by Carter and Ste-Marie (Carter \& Ste-Marie, 2017b). The motivational questionnaire used in this study consists of 21 items scored with a 7-point Likert scale with a higher score indicates better in perceived competence, task interest/enjoyment, and autonomy.

    Time frame: Three time points: pre-test (before intervention, 0 week), post-test (after all intervention sessions, up to 4 weeks), follow-up test (one month after intervention, up to 8 weeks)

  12. Corticomotor excitability

    Transcranial magnetic stimulation (TMS) device (The Magstim Company Ltd, Whitland, UK) will be used to determine the neurophysiology of corticomotor excitability.

    Time frame: Three time points: pre-test (before intervention, 0 week), post-test (after all intervention sessions, up to 4 weeks), follow-up test (one month after intervention, up to 8 weeks)

  13. Cortico-cortical connectivity

    Transcranial magnetic stimulation (TMS) device (The Magstim Company Ltd, Whitland, UK) will be used to determine the neurophysiology of corticocortical connectivity.

    Time frame: Three time points: pre-test (before intervention, 0 week), post-test (after all intervention sessions, up to 4 weeks), follow-up test (one month after intervention, up to 8 weeks)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • De-Jun Lim. Effects of Autonomy on Motor Learning in People with Parkinson's Disease. 2024. doi:10.6342/NTU202401486. uri:http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/94704
  • Chung CL, Mak MK, Hallett M. Transcranial Magnetic Stimulation Promotes Gait Training in Parkinson Disease. Ann Neurol. 2020 Nov;88(5):933-945. doi: 10.1002/ana.25881. Epub 2020 Sep 8. PubMed 32827221 ↗
  • Yang YR, Tseng CY, Chiou SY, Liao KK, Cheng SJ, Lai KL, Wang RY. Combination of rTMS and treadmill training modulates corticomotor inhibition and improves walking in Parkinson disease: a randomized trial. Neurorehabil Neural Repair. 2013 Jan;27(1):79-86. doi: 10.1177/1545968312451915. Epub 2012 Jul 10. PubMed 22785003 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Dec 2031, 63 months later.

Of 1,295 non-industry interventional studies with no phase under Parkinson Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 63 months is above that.

Counting every sponsor, half of 1,371 studies reached it within 25 months; a quarter within 11 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 15, 2026
First posted
Sep 22, 2026
StartEst.
Sep 23, 2026
Primary completionEst.
Dec 31, 2031
CompletionEst.
Dec 31, 2032
Last update
Sep 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07832695
Responsible party
Sponsor
First posted
Sep 22, 2026
Start date
Sep 23, 2026 (estimated)
Primary completion
Dec 31, 2031 (estimated)
Completion
Dec 31, 2032 (estimated)
Last update
Sep 22, 2026

Study contacts

Ya-Yun Lee, PhD
Contact
yayunlee@ntu.edu.tw
+886-2-33668155
Pei-Ling Wu
Contact
r14428005@ntu.edu.tw
+886-9-72197870
Graduate Institute of Physical Therapy
principal investigator · National Taiwan University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion